High Growth Tech Stocks In South Korea To Watch This August 2024

The South Korea stock market recently experienced a downturn, with the KOSPI index resting just above the 2,660-point plateau amid mixed performances from various sectors. Despite this volatility, high-growth tech stocks remain a focal point for investors looking to capitalize on innovative advancements and robust economic indicators in the region.

Top 10 High Growth Tech Companies In South Korea

Name	Revenue Growth	Earnings Growth	Growth Rating
Seojin SystemLtd	33.61%	52.05%	★★★★★★
IMLtd	20.76%	106.30%	★★★★★★
Bioneer	23.53%	97.58%	★★★★★★
FLITTO	32.60%	106.82%	★★★★★★
ALTEOGEN	64.22%	99.46%	★★★★★★
NEXON Games	31.70%	66.31%	★★★★★★
Devsisters	26.11%	65.92%	★★★★★★
Park Systems	23.49%	35.59%	★★★★★★
AmosenseLtd	24.04%	71.97%	★★★★★★
UTI	103.56%	122.67%	★★★★★★

Click here to see the full list of 50 stocks from our KRX High Growth Tech and AI Stocks screener.

Let's review some notable picks from our screened stocks.

ALTEOGEN (KOSDAQ:A196170)

Simply Wall St Growth Rating: ★★★★★★

Overview: ALTEOGEN Inc. is a biotechnology company specializing in the development of long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars, with a market cap of ₩16.76 billion.

Operations: The company generates revenue primarily from its biotechnology segment, which amounts to ₩90.79 million.

Alteogen's recent approval of Tergase® by Korea's MFDS marks a significant milestone, leveraging its Hybrozyme™ Technology to offer a recombinant hyaluronidase with over 99% purity. This product has multiple applications, from dermal filler removal to orthopedic pain management. With revenue projected to grow at 64.2% annually and earnings expected to increase by 99.5%, Alteogen is positioned for substantial growth despite current unprofitability. The company's strategic focus on high-purity biologics and innovative R&D investments underscores its potential in the biotech sector.

• Click here and access our complete health analysis report to understand the dynamics of ALTEOGEN.

• Gain insights into ALTEOGEN's historical performance by reviewing our past performance report.

ABL Bio (KOSDAQ:A298380)

Simply Wall St Growth Rating: ★★★★★☆

Overview: ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases, with a market cap of ₩1.63 trillion.

Operations: ABL Bio Inc. generates revenue primarily through its biotechnology segment, which reported ₩32.95 billion. The company is involved in developing therapeutic drugs targeting immuno-oncology and neurodegenerative diseases.

ABL Bio's focus on innovative R&D, with expenses constituting 33.5% of its revenue, underscores its commitment to advancing biopharmaceutical solutions. Despite current unprofitability, earnings are projected to grow at an impressive 93.9% per year over the next three years, indicating a strong growth trajectory. The recent private placement raising approximately ₩140B from prominent investors like Korea Development Bank and Atinum Growth Fund further strengthens its financial position for future endeavors in biotech advancements.

• Unlock comprehensive insights into our analysis of ABL Bio stock in this health report.

• Assess ABL Bio's past performance with our detailed historical performance reports.

HYBE (KOSE:A352820)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: HYBE Co., Ltd. engages in music production, publishing, and artist development and management businesses with a market cap of ₩7.81 trillion.

Operations: HYBE generates revenue through three primary segments: Label (₩1.28 trillion), Platform (₩361.12 billion), and Solution (₩1.24 trillion). The company's business operations encompass music production, publishing, and artist development and management.

HYBE's focus on expanding its digital content and global artist management has driven significant revenue growth, with earnings projected to grow 42.5% annually, outpacing the KR market's 28.8%. Despite a notable one-off loss of ₩189.4B in the last year, the company's robust R&D investment at 14% of revenue underscores its commitment to innovation. The recent share repurchase program aims to stabilize stock prices by buying back up to 150,000 shares before September 27, 2024.

• Click to explore a detailed breakdown of our findings in HYBE's health report.

• Explore historical data to track HYBE's performance over time in our Past section.

Make It Happen

• Get an in-depth perspective on all 50 KRX High Growth Tech and AI Stocks by using our screener here.
• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
• Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com